History

Late Shri Rai Bahadur Gujarmal Modi(August 9, 1902 January 22, 1976), an industrialist and
philanthropist, founded the Modi group of companies in 1933. It came into being with a sugar
unit put up by the patriarch himself and soon expanded with into other fields. It was his hard
work and dedication that gave birth to the industrial town of Modinagar. A dream that the he
himself nurtured and made true by building temples, charitable trust, and schools at Modinagar,
which are today synonymous to groups great success. He was also awarded the Padma Bhushan
by Government of India in 1968.
In 1972, the young 23-year old Umesh Kumar Modi, fresh out of BHU with a gold medal in
Chemical Engineering joined hands with his father and started exploring further opportunities. A
man of vision, he quickly learnt to grow beyond his area of expertise. Constantly looking for
growth opportunities, he expanded the humble sugar mill to shape it to the grand, successful
conglomerate it is today.
About Mr. Umesh K. Modi
Mr. Umesh K. Modi is the Group Chairman, President and CEO of the Umesh Modi Group. He
is the youngest son of Late Raibahadur Gujar Mal Modi. A name to reckon with in the Indian
Industry firmament, Mr. Umesh K. Modi has been instrumental in bringing the largest number of
internationally renowned collaborators to India.
He took the bold step of initiating joint ventures and alliances with European and American
companies in the 1980s when it was not as common as it is today. His mantra: in order to build
modern plants, have world-class partners via alliances and obtain a technology edge to succeed.

A foresight like this earned him the Man of the Year award for the year 1984 from the Ministry
of Industries.
A man of strict ethics, Mr. Umesh K. Modi puts the organisation before himself. He humbly
prefers to see himself as a trustee of the organisation rather than the master. A quick decision
maker, he spends his time personally strategising and expects this to be followed by strong
execution. Mr. Umesh K. Modi has held the prestigious Chairmanship of the various
organisations such as Steel Furnace Association of India, Western U.P. Sugar Mills Association,
Steel Wire Manufacturers Association of India, Sponge Iron Association of India as well as the
Presidentship of the Institute of Economic Studies. He continues to be an active member and
office bearer of many international organisations such as the Young Presidents Organisation,
Industrial Council of Development, among others. Besides this, he also heads a number of
corporations set up with international collaborators.
About Umesh Modi Group

Umesh Modi group, one of the largest industrial conglomerate in India, has made its
mark in the pharmaceuticals and cosmetics business. The groups interests are also spread

across diverse business ventures, the principal being:

Pharma & Healthcare
Cosmetics
Iron and steel
Sugar
Distillery & Alcohol
Power & Bio Energy
Writing Instruments
Travel and Tour

With 25 branch offices, 18 production units and over 8000 skilled professionals, Umesh Modi
Group is spread across India, Sri Lanka and Bangladesh. The group also has two R&D centres
and collaboration with 15 multinational companies that gives it a distinction of having one of the
largest numbers of foreign collaborations amongst leading business houses in India. Mr. Modis
approach to business has been largely conservative yet courageous. He took some bold steps and
initiated joint ventures and alliances with European and American companies in the 1980s when
it was not as much the norm as it is today. The Group today has many international brands
introduced in India such as Betadine, HepaMerz, Revlon, Senator, Silence, Bodysol and
Mederma.
Flying high, the group continues to work hard and keep its eyes fixed on the goal to deliver the
range of quality products. The mantra of Umesh Modi Group is achieve the benchmarked, then
set your own standards and surpass them too.
Vision And Mission
Vision: To deliver the best in class products and brands to the Indian consumer by collaborating
with leading International Organizations in the field of Manufacturing, Technology, Research &
Development and Marketing.
Mission: Umesh Modi Group to achieve a turnover of $ 1 billion by 2015.

Modi-Mundipharma Pvt. Ltd.

With the staggering success of Win-Medicare, Mr. Umesh K. Modi felt the need to expand his
pharmaceutical business further. And was born ModiMundipharma in 1990. It is a 50:50-joint
venture between the privately held Mundipharma Group of Switzerland (known as Purdue
Pharma in USA and Napp Laboratories in UK) and Mr. Umesh K. Modi. One of the largest,
privately held pharmaceutical company in India today, it is ranked 8th among the multinational
pharmaceutical corporations in India and 35th among the total of multinational and Indian
pharmaceutical companies in India (Source: ORG IMS MAT DEC 10). The Company has a
robust team totaling 1500 marketing and sales network professionals. It is effectively represented
in the domestic and International markets including Asian, East African, Middle East markets &
CIS Countries.
A rapidly growing pharmaceuticals company, Modi-Mundipharma draws its primary strength
from sound research and development as well as existing formulations of the Mundipharma
group of companies, world wide. Modi-Mundipharma offers world renowned formulations in
various therapeutic segments, encompassing cardiology, respiratory, gynaecology, pain, heart
diseases and other chronic therapy segments.

RESPIRATORY
CARDIOVASCULARS
UROLOGICALS
GYNAECOLOGICALS
ANALGESICS/NSAIDs

NUTRITIONAL
OTHERS

RESPIRATORY

SR.
NO BRAND

ACTIVE INGREDIENT

THERAPEUTIC USE

.
CR THEOPHYLLINE
1

UNICONTIN -E

ANTI-ASTHMATIC
ANHYDROUS 400 / 600mg

PHYLLOCONTIN

CR AMINOPHYLLINE

ANTI-ASTHMATIC

225/350 mg

CEBOFYL

ACEBROPHYLLINE 100MG

FOR C.O.P.D.

CR AMBROXOL
4

ACOCONTIN

MUCOLYTIC
HYDROCHLORIDE 75mg
AMBROXOL

ACOLYT

MUCOLYTIC
HYDROCHLORIDE 30mg/5ml

CARDIOVASCULARS

SR.
NO BRAND

ACTIVE INGREDIENT

THERAPEUTIC USE

.
NITROCONTIN

CR NITROGLYCERIN

2.6 / 6.4mg

ANTI-ANGINAL

ANTIDILCONTIN

CR DILTIAZEM HCI

ANGINAL/ANTIHYPERTENSIV
60

60mg TWICE-A-DAY
E
CR DILTIAZEM HCI

ANTI-

90/120/180mg ONCE-A-

ANGINAL/ANTIHYPERTENSIV

DAY

CR INDAPAMIDE 1.5 mg

ANTI-HYPERTENSIVE

DILCONTIN
3
XL

INDICONTIN

UROLOGICALS

SR.
NO BRAND

ACTIVE INGREDIENT

THERAPEUTIC USE

CR TAMSULOSIN 0.4/0.2 mg

FOR BPH

.
TAMCONTIN
1

TAMCONTIN

CR TAMSULOSIN 0.4/mg with

-D

DUTASTERIDE 0.5 mg

FOR BPH

GYNAECOLOGICALS

SR.
NO BRAND

ACTIVE INGREDIENT

THERAPEUTIC USE

.
CR FERROUS GLYCINE
SULPHATE EQUIVALENT TO
HAEMATINIC
1

IN

IRON

FECONTIN-F
DEFICIENCY
100mg ELEMENTAL IRON
WITH 0.5mg FOLIC ACID
CR FERROUS GLYCINE
SULPHATE EQUIVALENT TO
HAEMATINIC

DURING

PREGNANCY

&

100mg IRON WITH CR ZINC

2

FECONTIN-Z
SULPHATE

LACTATION
MONOHYDERATE 61.8mg &
0.5mg FOLIC ACID
MANAGEMENT OF PRE3

PYRICONTIN CR PYRIDOXINE HCI 100mg

MENSTRUAL SYNDROME
PYRICONTIN CR PYRIDOXINE HCI 100mg &

ANTI-FERTILITY
-F

ANALGESICS/NSAIDs

FOLIC ACID 5 mg

SR.
NO BRAND

ACTIVE INGREDIENT

THERAPEUTIC USE

.
1

MORCONTIN

CR MORPHINE SULPHATE

10/30/60/100mg

TRD-

CR TRAMADOL HCL 100mg

CONTIN

TWICE A DAY

TRD-MD

TRD-P

TRAMADOL MOUTH
DISPERSIBLE 50 mg
TRAMADOL 37.5mg &
PARACETAMOL 325 mg

ANALGESIC

ANALGESIC

ANALGESIC

ANALGESIC

DICLOFENAC SODIUM 50mg

5

FENAPLUS

WITH

ANALGESIC/ANTIINFLAMMATORY

PARACETAMOL 500mg
ENTERIC COATED
DICLOFENAC SODIUM 50mg
6

FENAPLUS

WITH

MR
500 mg PARACETAMOL 500mg
CHLORZOXAZONE

ANALGESIC/ANTIINFLAMMATORY
WITH
RELAXANT

MUSCLE

NUTRITIONAL

SR.
NO BRAND

ACTIVE INGREDIENT

THERAPEUTIC USE

SOYGROWTH

ISOLATED SOY PROTEIN

NUTRITIONAL

POWDER

SUPPLEMENT

ACTIVE INGREDIENT

THERAPEUTIC USE

OTHERS

SR.
NO BRAND
.
CR METOCLOPRAMIDE HCI
1

METOCONTIN

GASTRO-PROKINETIC
15mg

FLOXICONTIN

CR OFLOXACIN

ANTI-BACTERIAL
-O

400/800/600mg

Medical fraternity, across the length and breadth of India, perceive Modi-Mundipharma to be a
pharmaceutical company that offers long acting formulations in specialised therapeutic segments.
It has reached this position with consistent exposure of the brand benefits derived from Continus
controlled drug delivery, the differentiated and unique New Drug Delivery System (NDDS)
endorsed by medical practitioners across 70 countries world over.

A research & development collaboration agreement has been signed between ModiMundipharma, India and Mundipharma Laboratories GMBH under which Modi-Mundipharma
will undertake development of product formulations for Purdue Pharma.
The focus of Modi-Mundipharma is to continue offering state-of-the-art and latest high-tech
pharmaceutical solutions through introduction of differentiated products in the field of
respiratory, pain and heart diseases. It is effectively represented in the domestic and South Asian
markets.
Modi-Mundipharma markets:
Largest Nitrate brand in India
Second Largest O.S. Tramadol brand in India
Largest Plain O.S. Tramadol brand in India
Under its wing Modi-Mundipharma group has:
Win-Medicare Pvt. Ltd.; a subsidiary.
Win Healthcare; OTC arm of Win Medicare.
Mundipharma (Bangladesh) Pvt. Ltd.; a wholly owned subsidiary. (1st international pharma plant
of the group)
Modi-Revlon Pvt. Ltd., under which is
# Revlon Trading Bangladesh Pvt. Ltd.; a wholly owned subsidiary of Modi-Revlon.
# Revlon Lanka (Pvt.) Ltd.; a wholly owned subsidiary of Modi-Revlon.

# Kamakhya Cosmetics & Pharmaceuticals Pvt.Ltd.

Modi Omega; JV Collaboration between Modi Mundipharma & Omega.
Its licensing partners are:
Merz Pharmaceuticals, Germany
In licensing arrangement with Merz & Co. GMBH, Germany, for marketing:
HepaMerzTM, for hepatotherapeutics;
Axura for Alzheimers disease and
Contractubex & Mederma for treatment of scars.
Tillotts Pharma AG, Switzerland
In licensing arrangement with Tillotts Pharma AG, Switzerland, for marketing:
Asacol, a product for management of ulcerative colitis.
IBSA - Institut Biochimique SA, Switzerland
In licensing arrangement with IBSA - Institut Biochimique SA, Switzerland, for marketing:
Corion, Pregnorm, and Gonatrop F, the infertility management range.
Pierre Fabre France
In licensing arrangement with Pierre Fabre, France, for marketing:
Eludril

Arthrodont
Pansoral
Elugeltm
Elgydium
Sigma Tau, Italy
In licensing arrangement with Sigma Tau, Italy, for marketing:
Carnitor, for managing primary & secondary carnitine deficiency states.
Zambon,Italy
In licensing arrangement with Zambon, Italy, for marketing:
Fluimicil - For Respiratory Portfolio
Monurol - For Managing UTI.
Norgine UK
In licensing arrangement with Norgine, UK, for marketing:
Movicol
Moviprep
TRIGO Care International GMbH, Germany
In licensing arrangement for marketing:
Diagnopad Diagnostic kit for early detection of Diabetic Neuropathy.

Orion, Finland
In licensing arrangement with Orion, Finland for marketing:
Divigel For Hormone replacement Therapy